| Aug 7 |
EyePoint Pharmaceuticals GAAP EPS of -$0.58, revenue of $9.5M
|
| Aug 7 |
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 7 |
EyePoint Pharmaceuticals: Q2 Earnings Snapshot
|
| Aug 7 |
EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments
|
| Jul 15 |
Milestone Pharmaceuticals Refreshes Board of Directors
|
| Jun 26 |
EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
|
| Jun 19 |
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
|
| Jun 18 |
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
|
| Jun 5 |
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 29 |
Investing in EyePoint Pharmaceuticals (NASDAQ:EYPT) a year ago would have delivered you a 91% gain
|
